Skip to main content
Fig. 4 | BMC Neuroscience

Fig. 4

From: Re-engineering a neuroprotective, clinical drug as a procognitive agent with high in vivo potency and with GABAA potentiating activity for use in dementia

Fig. 4

Beneficial effects seen in LTP from NMZ treatment in APP/PS1 mice. a, b LTP was measured in the CA1 region of hippocampal sections in 4 month old male APP/PS1 mice or littermate controls (n = 5–8) treated with CMZ (a) or NMZ (b). NMZ showed restoration of LTP in APP/PS1 mice to WT levels, whereas the effects of CMZ were not significant. Statistical significance was analyzed by two-way ANOVA with repeated measures: WT veh (n = 6) vs. WT NMZ (n = 6): F(1,10) = 1.106 p > 0.05 No Sig.; WT veh vs. APP/PS1 veh: F(1,12) = 18.86 p < 0.05 Sig; APP/PS1 veh (n = 8) vs. APP/PS1 NMZ (n = 7): F(1,13) = 17.71 p < 0.05 Sig; WT NMZ vs. APP/PS1 NMZ: F(1,11) = 0.02351 p > 0.05 No Sig

Back to article page

BMC Neuroscience

ISSN: 1471-2202

Contact us